Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
Adjuvants, Immunologic
/ administration & dosage
Adult
Cohort Studies
Databases, Factual
/ trends
Female
Glatiramer Acetate
/ administration & dosage
Humans
Immunosuppressive Agents
/ administration & dosage
Injections, Intramuscular
Interferon beta-1a
/ administration & dosage
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
/ diagnosis
Treatment Outcome
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
12 01 2021
12 01 2021
Historique:
received:
11
12
2019
accepted:
24
08
2020
pubmed:
8
10
2020
medline:
28
1
2021
entrez:
7
10
2020
Statut:
ppublish
Résumé
To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-β-1a), we applied a previously published statistical method aimed at identifying patients' profiles associated with efficacy of treatments. Data from 2 independent multiple sclerosis datasets, a randomized study (the Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis [CombiRx] trial, evaluating GA vs IFN-β-1a) and an observational cohort extracted from MSBase, were used to build and validate a treatment response score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. The overall ARR ratio of GA to IFN-β-1a in the CombiRx trial was 0.72. The response score (made up of a linear combination of age, sex, relapses in the previous year, disease duration, and Expanded Disability Status Scale score) detected differential response of GA vs IFN-β-1a: in the trial, patients with the largest benefit from GA vs IFN-β-1a (lower score quartile) had an ARR ratio of 0.40 (95% confidence interval [CI] 0.25-0.63), those in the 2 middle quartiles of 0.90 (95% CI 0.61-1.34), and those in the upper quartile of 1.14 (95% CI 0.59-2.18) (heterogeneity We demonstrate the possibility of a criterion, based on patients' characteristics, to choose whether to treat with GA or IFN-β-1a. This result, replicated on an independent real-life cohort, may have implications for clinical decisions in everyday clinical practice.
Identifiants
pubmed: 33024022
pii: WNL.0000000000010991
doi: 10.1212/WNL.0000000000010991
pmc: PMC7905777
doi:
Substances chimiques
Adjuvants, Immunologic
0
Immunosuppressive Agents
0
Glatiramer Acetate
5M691HL4BO
Interferon beta-1a
XRO4566Q4R
Types de publication
Journal Article
Observational Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e214-e227Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR003167
Pays : United States
Informations de copyright
© 2020 American Academy of Neurology.
Références
N Engl J Med. 2012 Sep 20;367(12):1098-107
pubmed: 22992073
Mult Scler. 2020 Aug;26(9):1064-1073
pubmed: 31144577
BMC Neurol. 2018 Oct 3;18(1):162
pubmed: 30285675
Ann N Y Acad Sci. 1965 Mar 31;122:552-68
pubmed: 14313512
J Am Stat Assoc. 2013 Jan 1;108(502):527-539
pubmed: 24058223
Mult Scler. 2006 Dec;12(6):769-74
pubmed: 17263005
Mult Scler. 2015 Aug;21(9):1159-71
pubmed: 25480857
Ann Neurol. 2005 Dec;58(6):840-6
pubmed: 16283615
BMC Med. 2019 Jun 18;17(1):113
pubmed: 31208412
Am J Epidemiol. 2016 Apr 15;183(8):758-64
pubmed: 26994063
Ann Neurol. 2001 Jul;50(1):121-7
pubmed: 11456302
J Neurol. 2014 Apr;261(4):773-83
pubmed: 24535134
N Engl J Med. 2012 Mar 15;366(11):1000-9
pubmed: 22417253
N Engl J Med. 2012 Sep 20;367(12):1087-97
pubmed: 22992072
Mult Scler Relat Disord. 2012 Apr;1(2):81-6
pubmed: 25876935
Ann Neurol. 2013 Mar;73(3):327-40
pubmed: 23424159
Brain. 2017 Sep 1;140(9):2426-2443
pubmed: 29050389
Ann Neurol. 2007 Jan;61(1):14-24
pubmed: 17262850